Triple combinations in chronic obstructive pulmonary disease – is three better than two?

Bibliography

• National Institute for Health and Clinical Excellence. NICE clinical guideline 101. Available from: http://www.nice.org.uk/nicemedia/live/13 029/49397/49397.pdf [Accessed 20 September 2014]
   Google Scholar
• GOLD strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/uploads/users/fi les/GOLD_Report2014_Feb07.pdf [Accessed 20 September 2014]
   Google Scholar
• James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management and outcomes of COPD patients in primary care, 2000–2009: a retrospective cohort study. NPJ Prim Care Respir Med 2014;24:14015
   Google Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106:989-97
   PubMed Web of Science ®Google Scholar
• Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One 2014;9:e105296
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012;48:785-94
   PubMed Web of Science ®Google Scholar
• Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;3
   Google Scholar
• Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD 2011;8:206-43
   PubMedGoogle Scholar
• Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012;25:40-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med 2014;25:491-5
   Google Scholar
• Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung 2014;92:649-52
   Google Scholar
• Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration 2013;86:280-7
   Google Scholar
• Kraemer M, Ellis A, Baldwin M, et al. Dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD – a network meta-analysis of FEV1 [abstract]. Value Health 2012;15:A560
   Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94
   PubMed Web of Science ®Google Scholar
• Vincken W, Auman J, Goyal P, Altman P. Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: a post-hoc analysis from the GLOW6 study [abstract]. Eur Respir J 2014;44:P2410
   Google Scholar
• Reisner C, Fernandez C, Darken P, et al. Pearl’s PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003 [abstract]. Eur Respir J 2014;44:1891
   Google Scholar
• Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:2489-99
   PubMed Web of Science ®Google Scholar
• Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med 2010;104:412-17
   PubMed Web of Science ®Google Scholar
• Bateman ED, Mahler DA, Vogelmeier CF, et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014;8:357-79
   PubMed Web of Science ®Google Scholar
• Reilly JJ. Stepping down therapy in COPD. N, Engl J, Med. 2014;371:1340-1
   Google Scholar
• Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 2014;15:85-96
   PubMed Web of Science ®Google Scholar
• Giembycz MA, Newton R. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Clin Chest Med 2014;35:203-17
   Google Scholar
• Calverley PM, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012;7:375-82
   Web of Science ®Google Scholar
• Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J 2014;44:475-82
   PubMed Web of Science ®Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 2013;346:414-23
   PubMed Web of Science ®Google Scholar